Clinical Trials on Essential Hypertension, Dyslipidemia

Total 13784 results

Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia (FIESTA)

Essential Hypertension, Dyslipidemia

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia

Essential Hypertension, Dyslipidemia

Korea, Republic of
GlaxoSmithKline

Completed

GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol

Dyslipidaemia | Dyslipidaemias

Germany, Estonia, Belgium, France, Netherlands, Denmark, Portugal, Norway, Sweden, Lithuania, Finland
Boryung Pharmaceutical Co., Ltd

Completed

Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia (FIRST)

Dyslipidemia | Essential Hypertension

Korea, Republic of
Daewoong Pharmaceutical Co. LTD.

Unknown

Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia

Hypertension | Dyslipidemias

Korea, Republic of
Takeda

Withdrawn

A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. (ALIVE)

Essential Hypertension With Stable Angina and Dyslipidemia

Japan
GlaxoSmithKline

Completed

Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.

Healthy Subjects | Dyslipidaemia | Dyslipidaemias

United Kingdom
Xention Ltd

Completed

Study of the Electrocardiographic Effects of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Statin Therapy Results in the Real World Practice in the Czech Republic (STEP)

Dyslipidaemia

Czech Republic
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia

Dyslipidaemia

Denmark, United States, Slovakia
Novartis Pharmaceuticals

Completed

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Dyslipidaemia

Jordan, United States, Taiwan
AstraZeneca

Completed

48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

Dyslipidaemia
Daewoong Pharmaceutical Co. LTD.

Unknown

Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451

Hypertension, Dyslipidemia

Korea, Republic of
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Dyslipidaemias

United States, Canada
GlaxoSmithKline

Completed

Study to Test GSK256073 in Patients With Dyslipidemia

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

Dyslipidaemias

United States
Boryung Pharmaceutical Co., Ltd

Completed

A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia (FIMASTAR)

Hypertension and Dyslipidemia

Korea, Republic of
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
AstraZeneca

Completed

Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

Dyslipidaemia

Russian Federation
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS) (IRIS)

Hypercholesterolemia | Dyslipidaemia
Jeil Pharmaceutical Co., Ltd.

Completed

Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

Dyslipidemia With Hypertension

Korea, Republic of
GlaxoSmithKline

Completed

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

Dyslipidaemias

United States
AstraZeneca

Completed

CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II) (CEPHEUSII)

Dyslipidaemia

Russian Federation
Xention Ltd

Completed

Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES) (ARIES)

Hypercholesterolemia | Dyslipidaemia
Addpharma Inc.

Completed

A Study to Evaluate the Efficacy and Safety of AD-209

Hypertension, Essential

Korea, Republic of
Bayer

Completed

Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions

Hypertension, Essential

Germany
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Dyslipidemia Patients With Hypertension

Korea, Republic of
IlDong Pharmaceutical Co Ltd

Not yet recruiting

A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.

Hypertension, Dyslipidemia
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP) (STARSHIP)

Hypercholesterolemia | Dyslipidaemia
Universidade Federal de Santa Maria

Completed

Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients

Healthy Volunteers | Hypertension, Essential

Brazil
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet

Hypertensive Patients With Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348

Hypertension and Dyslipidemia

Korea, Republic of
Cytos Biotechnology AG

Completed

Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension

Mild Essential Hypertension | Moderate Essential Hypertension

Switzerland
Sulaiman AlRajhi Colleges

Unknown

The Association Between Serum β-hydroxybutyrate and Levels of Systemic Hypertension (BHB-RCT)

Hypertension, Essential | β-hydroxybutyrate
Daewon Pharmaceutical Co., Ltd.

Completed

Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers

Hypertension and Dyslipidemia
GlaxoSmithKline

Completed

A Second Study to Determine the Effect of GSK256073A on HVTs

Healthy Subjects | Dyslipidaemias

United States
Bayer

Completed

Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed

Hypertension, Essential

Germany
Yuhan Corporation

Completed

PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and Rosuvastatin

Dyslipidemia & Hypertension

Korea, Republic of
GlaxoSmithKline

Completed

Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers

Healthy Subjects | Dyslipidaemias

United States
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348 (CKD-348)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386

Hypertension and Dyslipidemia

Korea, Republic of
Jeil Pharmaceutical Co., Ltd.

Completed

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

Hypertension With Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin. (CKD-345)

Essential Hypertension | Hyperlipidemia

Korea, Republic of
Novartis

Completed

A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia

Hypercholesterolemia | Essential Hypertension

Switzerland, Germany
Chong Kun Dang Pharmaceutical

Completed

Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine (CKD-345 DDI)

Essential Hypertension | Hyperlipidemia

Korea, Republic of

3

Subscribe